Psychedelics are a hallucinogenic class of
psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of
psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment of any
psychiatric disorder with
psychedelics (excluding
ketamine) are summarized and analyzed. 70 registered studies were identified from a clinicaltrials.gov search on December 3, 2020. The majority of studies aim to investigate
methylenedioxymethamphetamine (
MDMA) (45.7%) and
psilocybin (41.4%). Studies evaluating ayahuasca,
lysergic acid diethylamide (
LSD),
ibogaine hydrochloride, salvia divinorum, 5-MeO-DMT and DMT
fumarate were less common at 1.4%, 4.2%, 2.8%, 1.4%, 1.4% and 1.4% of total registered studies, respectively. Most of the studies on
MDMA,
psilocybin, ayahuasca and salvia divinorum investigated their
therapeutic effect on
post-traumatic stress disorder (
PTSD) and
major depressive disorder (MDD).
LSD was investigated for MDD, anxiety, and severe somatic disorders and
ibogaine hydrochloride was investigated for substance and
alcohol use disorders. 5-MeO-DMT and DMT
fumarate were both investigated for MDD. Only 21/70 registered studies had published results with the majority not yet completed. In view of the large number of ongoing studies investigating
psychedelics, it is imperative that these studies are considered by researchers and stakeholders in deciding the most relevant research priorities for future proposed studies.